Natera has initiated a significant interventional study aimed at melanoma treatment.
Natera Inc has announced the launch of a randomized, Signatera™-guided interventional study focused on melanoma. This study aims to evaluate how effective its Signatera™ technology is in guiding treatment decisions for melanoma patients, potentially enhancing personalized treatment strategies. The stock closed at US$384.99, reflecting a 1.27% decline for the day and a 4.29% decrease over the past week, though it has gained 20.53% in the last month and 72.85% year-to-date.
Investor takeaway: Investors should monitor the outcomes of this study as it may impact Natera's market position in the oncology sector.
Advertisement
Natera Inc
NTRA.US
NTRA.US
Natera Inc
WealthAwesomeMarket cap
$59.59B
52W high
$437.41
52W low
$181.00
1W change
-0.84%
Beta
1.50
Analyst Price Targets
Based on 23 analysts covering NTRA · as of Oct 21, 2026
Wall Street analysts forecast NTRA stock price to rise 2.0% over the next 12 months.
Consensus
Strong Buy4.61 / 5.00
Avg. Target
C$409.57
+2.0% Upside
Previously C$403.89 on Oct 16, 2026
Current Price
C$401.37
Last close
Analyst Breakdown (23 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on NTRA's historical volatility
30-Day Vol
40.5%
Annualized
90-Day Vol
50.0%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$479.84
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$425.99 | C$370.40 – C$489.91 |
| 60 trading days | C$452.11 | C$371.00 – C$550.96 |
| 90 trading days | C$479.84 | C$376.64 – C$611.33 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Natera's stock volume increased to 839,539 shares.
This volume is 1.58 times higher than the 20-day average of 1,785,144 shares, indicating heightened trading activity amid the announcement.
Bull case
If the study validates Signatera™'s effectiveness, it could lead to increased adoption and revenue growth in the oncology market.
Bear case
However, if the study fails to show significant benefits, it could damage Natera's credibility and market performance in the competitive health care sector.
Natera's New Study Announcement
Advertisement
Natera Inc has announced a new randomized interventional study guided by its Signatera™ technology, specifically targeting melanoma treatment. This innovative approach aims to personalize treatment for melanoma patients, potentially improving outcomes. The study's design underscores Natera's commitment to advancing precision medicine in oncology. With a current market capitalization of US$57.75 billion and a negative profit margin of 7.1%, the company is focused on enhancing its position in the health care sector.
Stock Performance and Trading Volume Insights
Following the announcement, Natera's stock closed at US$384.99, reflecting a daily decline of 1.27%. The trading volume reached 839,539 shares, significantly above the 20-day average of 1,785,144 shares, indicating increased investor interest in the stock. Over the past month, the stock has appreciated by 20.53%, while year-to-date performance shows a remarkable gain of 72.85%. The stock is currently trading at 15.1% above its 50-day moving average of US$334.34 and 54.0% above its 200-day moving average of US$250.04.
What to Watch Next for Natera
Investors should keep an eye on the progress and results of the randomized study, as successful outcomes could bolster Natera's market position and enhance the adoption of its Signatera™ technology. Additionally, the stock trades within a 52-week range of US$167.99 to US$437.41, and the average analyst target stands at US$377.43, suggesting an implied move of -2.0% from the last closing price. Market reactions in the coming weeks may provide insights into investor sentiment regarding the company's future prospects.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
